Abstract
Objective To construct a predictive model for the Sharp/van der Heijde score (SHS) and assess its applicability in clinical research settings.
Methods First, we built a rheumatoid arthritis (RA) image database linked to clinical information. We then constructed the prediction model in three steps: orientation, detection, and damage prediction. We assessed whether the SHS generated by our model replicated known findings on the association between radiographic progression and serological markers. Finally, after characterizing the SHSs of 4,264 patients using hierarchical clustering, we constructed a predictive model for joint destruction using a graph convolutional network (GCN).
Results We built a model with an accuracy of 100% in the correction of image orientation using EfficientNet and constructed a model with all predicted joint coordinates within 10 pixels of the correct coordinates using U-Net. In the damage prediction phase, the EfficientNet-based model combined with the modules achieved correlation coefficients of 0.879 for erosion and 0.868 for joint space narrowing between the model and expert, exceeding that of the previous best model. Our model replicated the known finding of erosion progression’s association with serologically positive patients. The areas under the curve for predicting finger and wrist erosion in the GCN model were 0.800 and 0.748, respectively. We observed that clusters generated by hierarchical clustering ranking in the top 10 were important features in the GCN for predicting erosion.
Conclusion We constructed a high-performance scoring model for SHSs applicable to clinical research. Our analysis revealed that clusters are important for predicting erosion using the GCN.
What is already known about this subject?
► Several deep learning models that automatically predict Sharp/van der Heijde scores (SHSs) have been reported. However, the accuracy of their joint detection and erosion prediction was insufficient, and more importantly their clinical applicability was unclear.
► Models for predicting joint destruction using clinical factors have been constructed with arbitrary factor selection by humans. No report has demonstrated the usefulness of deep learning models in predicting joint destruction using large SHS datasets.
What does this study add?
► Our deep learning model showed a high performance in both joint space narrowing and erosion, replicated previous findings on association between joint destruction and serological markers, thereby demonstrating, for the first time, that deep learning models could be clinically applicable in estimating SHSs.
► We also demonstrated that a graph convolutional network (GCN) is a high performance model in predicting radiographic progression.
How might this impact clinical practice or future developments?
► We believe our model will be an essential tool for future studies, such as in genome-wide association studies (GWAS) for joint destruction on a scale of thousands to millions, which is difficult to achieve with human scoring. Ultimately, data from large-scale GWAS will be integrated into the GCN to build a powerful model for precision medicine.
Competing Interest Statement
S.H. declares no conflicts of interest. K.I. received speaker fees from Asahi Kasei Pharma Co.; Astellas Pharma Inc.; AbbVie Japan GK; Ayumi Pharmaceutical Corporation; Bristol Myers Squibb Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Eisai Co., Ltd.; Eli Lilly Japan K. K.; Janssen Pharmaceutical K. K.; Kaken Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Co.; Pfizer Japan Inc.; Takeda Pharmaceutical Co., Ltd.; Teijin Pharma Ltd.; and UCB Japan Co. Ltd. The Division of Multidisciplinary Management of Rheumatic Diseases is an endowment department supported by an unrestricted grant from Ayumi Pharmaceutical Corp., Chugai Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Co.; Mochida Pharmaceutical Co., Ltd.; Nippon Kayaku Co., Ltd.; and Teijin Pharma Ltd. K. Y. received lecture or speaker fees from Astellas Pharma Inc.; AbbVie Japan GK; Bristol Myers Squibb Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Eli Lilly Japan K. K.; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Co.; Pfizer Japan Inc.; and Takeda Pharmaceutical Co. Ltd. E.T. received lecture or consulting fees from AbbVie Japan GK; Asahi Kasei Corp.; Astellas Pharma Inc.; Ayumi Pharmaceutical Co.; Chugai Pharmaceutical Co., Ltd.; Eisai Co., Ltd.; Eli Lilly Japan K.K.; GlaxoSmithKline K. K.; Kyowa Pharma Chemical Co., Ltd.; Janssen Pharmaceutical K.K.; Mochida Pharmaceutical Co., Ltd.; Pfizer Japan Inc.; Takeda Pharmaceutical Co., Ltd.; and Teijin Pharma Ltd. M.H. received research grants from AbbVie Japan GK; Asahi Kasei Corp.; Astellas Pharma Inc.; Ayumi Pharmaceutical Co.; Bayer Yakuhin Co., Ltd.; Boehringer Ingelheim Japan, Inc.; Bristol Myers Squibb Co., Ltd.; Chugai Pharmaceutical Co.; Daiichi-Sankyo, Inc.; Eisai Co., Ltd.; Eli Lilly Japan K. K.; Kaken Pharmaceutical Co., Ltd.; Kissei Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Co.; Mochida Pharmaceutical Co., Ltd.; Nippon Kayaku Co., Ltd.; Nippon Shinyaku Co., Ltd.; Taisho Pharmaceutical Co., Ltd.; Teijin Pharma Ltd.; UCB Japan Co., Ltd.; and Viatris Japan. M.H. received speaker fees from AbbVie Japan GK; Asahi Kasei Corp.; Astra Zeneca K. K.; Ayumi Pharmaceutical Co.; Boehringer Ingelheim Japan, Inc.; Bristol Myers Squibb Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Eisai Co., Ltd.; Eli Lilly Japan K. K.; GlaxoSmithKline K. K.; Gilead Sciences Inc.; Janssen Pharmaceutical K. K.; Kissei Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Co.; Mochida Pharmaceutical Co., Ltd.; Nippon Kayaku Co., Ltd.; Nippn Shinyaku Co., Ltd.; Novartis Japan; Ono Pharmaceutical Co., Ltd.; Pfizer Japan Inc.; Taisho Pharmaceutical Co., Ltd.; Teijin Pharma Ltd.; and UCB Japan. M.H. is a consultant for AbbVie; Boehringer Ingelheim; Bristol Myers Squibb Co.; Kissei Pharmaceutical Co., Ltd.; and Teijin Pharma.
Funding Statement
This work was supported by the ASIA PACIFIC LEAGUE OF ASSOCIATIONS FOR RHEUMATOLOGY Research Grant 2021 and JSPS KAKENHI: Grant Numbers JP22H03206 and JP19K09583
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IORRA cohort studies (#2952-R and #2922-R16)from which the data for this study were approved by the ethics committee of Tokyo Women's Medical University and informed consent was obtained from all patients before each survey.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data using analysis that support the findings of this study are available on reasonable request to the authors. The imaging data are not publicly available due to restrictions (containing information that could compromise the privacy of research participants) Code is available at https://github.com/honda-s691470/SHS_NET/ and https://github.com/honda-s691470/GCN_SHS_NET
